| Population 2017 |
<1 million |
| |
| | | | | |
| Estimates of TB burden*, 2017 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
0.021 |
(0.02–0.021) |
4.8 |
(4.7–5) |
| Mortality (HIV+TB only) |
0 |
(0–<0.01) |
0 |
(0–0.03) |
| Incidence (includes HIV+TB) |
0.27 |
(0.23–0.32) |
64 |
(55–74) |
| Incidence (HIV+TB only) |
<0.01 |
(<0.01–<0.01) |
0.54 |
(0.35–0.77) |
| Incidence (MDR/RR-TB)** |
0 |
(0–0) |
0 |
(0–0) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2017 |
| |
0-14 years |
> 14 years |
Total |
| Females |
0.014 |
(0.013–0.014) |
0.089 |
(0.081–0.097) |
0.1 |
(0.094–0.11) |
| Males |
0.015 |
(0.014–0.015) |
0.16 |
(0.14–0.17) |
0.17 |
(0.15–0.19) |
| Total |
0.029 |
(0.027–0.03) |
0.24 |
(0.21–0.28) |
0.27 |
(0.23–0.32) |
| |
| | | | | |
| TB case notifications, 2017 |
|
| Total cases notified |
238 |
| Total new and relapse |
238 |
| - % tested with rapid diagnostics at time of diagnosis |
|
| - % with known HIV status |
100% |
| - % pulmonary |
81% |
| - % bacteriologically confirmed among pulmonary |
93% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2017 |
87% (75–100) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2017 |
0.08 (0.07–0.09) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2017 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
2 |
<1% |
| - on antiretroviral therapy |
2 |
100% |
| |
| | | | | |
| Drug-resistant TB care, 2017 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
0
(0–2) |
| Estimated % of TB cases with MDR/RR-TB |
0% (0–2.1) |
0% (0–34) |
|
| % notified tested for rifampicin resistance |
75% |
90% |
179 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
0 |
| Laboratory-confirmed cases |
MDR/RR-TB: 0, XDR-TB: 0 |
| Patients started on treatment **** |
MDR/RR-TB: 0, XDR-TB: 0 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2016 |
72% |
242 |
| Previously treated cases, excluding relapse, registered in 2016 |
|
0 |
| HIV-positive TB cases registered in 2016 |
100% |
3 |
| MDR/RR-TB cases started on second-line treatment in 2015 |
|
0 |
| XDR-TB cases started on second-line treatment in 2015 |
|
0 |
| |
| | | | | |
| TB preventive treatment, 2017 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
0% (0–0) |
| |
| | | | | |
| TB financing, 2018 |
|
| National TB budget (US$ millions) |
|
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed | | |
| | | | | |